Dana-Farber Cancer Institute has announced a $40 million commitment from the Paula and Rodger Riney Foundation in support of multiple myeloma research.

The largest single grant for multiple myeloma research in the institute’s history will renew support for preclinical experiments to identify novel targets and develop new medicines and immune-based therapies for patients; fund clinical research designed to test novel myeloma therapies, alone and in combination with standard and experimental treatments, to improve patient outcomes; and provide support for co-locating myeloma labs at Dana-Farber to facilitate greater cohesion and collaboration.

To date, the Riney Foundation has committed nearly $60 million to Dana-Farber, including the latest grant, a $16.5 million gift in 2019 to establish the Riney Family Multiple Myeloma Initiative, and gifts over the past two years totaling $2.6 million to establish the Riney Family Fund for COVID-19 and Multiple Myeloma Research at Dana-Farber.

“My own journey as a myeloma patient — and knowing how many others are also living with this disease — has led us to seek out the individuals, teams, and organizations that are on the leading edge of research,” said Rodger Riney. “There is no time to waste in the pursuit of better understanding, treatment, and cures.”

(Photo courtesy of the Paula and Roger Riney Foundation)